Providence VA Medical Center

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Providence VA Medical Center sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 1 currently recruiting 8 completed later-stage tilt top decile by trial count

Providence VA Medical Center: 9 sponsored US clinical trials, 1 recruiting.

Providence VA Medical Center sponsors 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 2 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Coronary Arteriosclerosis, with 1 trials.

Top-decile sponsor footprint

Providence VA Medical Center ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Where Providence VA Medical Center enrollment is open (later-stage tilt)

1 recruiting of 9 indexed (11% open); 8 completed (89%).

Phase mix: 2 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Coronary Arteriosclerosis (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Providence VA Medical Center: open-pipeline peers nationwide

Peers matched on 9 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Providence VA Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40%50% Total trials Recruiting share Providence VA Medical Center4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi companyADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Providence VA Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Providence VA Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Providence VA Medical Center page

9 registered trials is a research-attention snapshot, not an endorsement of Providence VA Medical Center or any single study.

  • 1 of Providence VA Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Coronary Arteriosclerosis is the condition Providence VA Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Coronary Arteriosclerosis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Providence VA Medical Center pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.